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ness	 increased	 by	 0.09	kPa	 (95%	 CI	 0.05,	 0.13,	 P	<	0.001).	 There	 was	 significant	
correlation	between	 liver	 stiffness	and	biopsy	 results	 (Tau-	b	=	0.29,	P	=	0.042).	Of	
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only	 20%	of	 those	 infected	 know	 about	 their	 diagnosis.	Of	 those	






infection in children remains largely undiagnosed.
Russia	 has	 one	 of	 the	 highest	 burdens	 of	HCV	 infection	 glob-
ally	with	an	estimated	seroprevalence	of	4.3%	and	the	highest	ab-




ied widely across regions, from 13 to 68.6 Over the last few years, 
the	reported	CHC	incidence	has	gradually	decreased	to	35-	36	per	
100	000	 in	 2016-	2017.7	 Genotype	 (GT)	 1b	 is	 the	 most	 prevalent	
genotype	accounting	for	55%	of	all	cases,	followed	by	GT3	(35%).8




per	100	000	children	in	2016-	2017.7 Vertical transmission was the 
most	common	mode	of	acquisition	accounting	for	two-	thirds	of	new	
infections,	with	 anti-	HCV	 prevalence	 among	 pregnant	women	 re-







2  | MATERIAL S AND METHODS
An observational study of children and adolescents with chronic 
HCV	followed	up	in	three	Russian	hepatology	centres	was	conducted	
in	November	2014	to	July	2015.	The	participating	centres	covered	




A total of 100 children seen consecutively in each centre and 















fected, duration of diagnosed infection was calculated as time from 
date of diagnosis.
The	 mode	 of	 transmission	 was	 reported	 by	 participating	
clinics	 as	 vertical	 (mother	 is	 known	 to	 have	 HCV),	 suspected	
205	 treated	with	 IFN-	based	 regimens,	 100	 (49%)	 had	 SVR24.	Most	 children	 (191,	
93%)	experienced	adverse	reactions,	leading	to	treatment	discontinuation	in	6	(3%).	
In	conclusion,	a	third	of	children	acquired	HCV	via	nonvertical	routes	and	a	substan-
tial	 proportion	of	 those	with	 liver	 biopsy	 had	 advanced	 liver	 disease.	Only	 half	 of	
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moderate	 (7.0	 to	 <9.0	kPa)	 and	 severe	 increase	 (≥9.0	kPa);	 ≥9	kPa	
was	taken	as	predictor	of	severe	fibrosis	(≥F3).15,16


















effects	model	 to	allow	for	correlation	 in	 repeated	measurements	 in	
individuals.	The	model	assessed	the	association	between	age	at	TE,	
sex,	genotype,	centre	and	mode	of	infection.
Analyses	 were	 conducted	 using	 STATA/IC	 15.1	 (Stata	 Corp,	
College	Station,	TX,	USA).
3  | RESULTS
A	 total	 of	 301	 children	 under	 follow-	up	 were	 included	 101	 were	














testing, had elevated liver transaminases or were screened before in-
vasive	procedures	(Supporting	information	Table	S2).
At	last	follow-	up,	in	children	with	vertical,	suspected	healthcare-	
associated	 and	 other/unknown	 modes	 of	 infection,	 respectively,	
median	 age	 was	 8.9	 [6.0,	 11.8],	 15.2	 [12.7,	 17.3]	 and	 12.5	 [10.7,	
17.5]	years	and	duration	of	diagnosed	 infection	was	6.0	 [3.0,	8.4],	
4.2	[2.5,	7.9]	and	3.5	[1.8,	7.0].	Six	vertically	infected	children	were	
HIV-	coinfected;	 one	 with	 suspected	 nosocomial	 infection	 was	
HBV-	coinfected.
3.1 | Laboratory investigations
At	 last	 visit,	 82	 (27%)	 children	 had	 ALT	 >40	IU/L,	 88	 (29%)	 AST	
>40	IU/L	 (108	 (36%)	 had	ALT	 >40	IU/L	 or	AST	 >40	IU/L),	 six	 (2%)	
had	platelets	<150	×	109/L	and	15	(5%)	had	albumin	<35	g/L.	No	dif-
ferences were observed by duration of infection/age in vertically 














two	 (21%)	vertically	 infected	children	had	a	biopsy	vs	50	 (48%)	of	
those with nonvertical infection but this difference was nonsignifi-





at	 diagnosis	was	10.4	 [7.1,	 14.1]	 years,	with	 range	of	 2.1-	17.8	years.	
Cirrhosis	was	identified	at	liver	biopsy	in	one	15-	year-	old	adolescent	
in	whom	infection	acquired	through	contaminated	blood	products	was	







liver stiffness (r	=	0.22,	P	=	0.001)	 (Figure	1).	Moderate	 increase	




treatment	before	 the	 last	TE,	mean	 liver	 stiffness	decreased	 from	
TABLE  1 Bridging	fibrosis	and	cirrhosis	detected	on	liver	biopsy	by	patient	characteristics
All with liver biopsy No bridging fibrosis Bridging fibrosis or cirrhosis P- value
N (%) or median [IQR]
All 92 53 (58) 39 (42)
Sex
Male 44 (48) 24 (55) 20 (45) 0.569
Female 48 (52) 29 (60) 19 (40)
Mode of infection
Vertically infected 42 (46) 27	(64) 15 (36) 0.235
Not vertically infected 50 (54) 26 (52) 24 (48)
HCV	genotype
1a/b 64	(70) 35 (55) 29 (45) 0.391
2/3 28 (30) 18 (64) 10 (36)
Centre
Moscow 68	(74) 38 (56) 30 (44) 0.181
St	Petersburg 11 (12) 9 (82) 2 (18)
Krasnoyarsk 13 (14) 6 (46) 7	(54)
All	patients
Age	at	biopsy,	Median	[IQR] 9.4	[6.1,	13.0] 8.8	[6.0,	12.2] 10.2	[7.1,	14.1] 0.179
≤5	y 21 (23) 13 (62) 8 (38)
6-	10	y 35 (38) 21 (60) 14 (40)
11-	15	y 27	(29) 14 (52) 13 (48)




6.3	[4.7,	9.0] 6.1	[4.5,	7.3] 7.8	[5.0,	10.2] 0.185
≤5	y 18 (43) 12	(67) 6 (33)
6-	10	y 18 (43) 12	(67) 6 (33)
>10	y 6 (14) 3 (50) 3 (50)
Nonvertically	infected	(n	=	50)
Age	at	biopsy,	Median	[IQR] 11.8	[9.3,	14.8] 11.8	[9.2,	14.8] 11.7	[9.5,	14.8] 0.892
≤5	y 3 (6) 1 (33) 2	(67)
6-	10	y 17	(34) 9 (53) 8	(47)
11-	15	y 22 (44) 12 (55) 10 (45)
>15	y 8 (16) 4 (50) 4 (50)
Duration of diagnosed infection at 
biopsy,	Median	[IQR]
1.9	[0.5,	8.8] 6.2	[1.2,	10.5] 0.6	[0.4,	2.9] 0.019
≤5	y 31 (62) 12 (39) 19 (61)
6-	10	y 11 (22) 9 (82) 2 (18)
>10	y 8 (16) 5 (63) 3	(27)
IQR,	interquartile	range.
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TABLE  2  Increased	liver	stiffness	detected	on	TE	by	patient	characteristics
All with TE No increase (<5 kPa)
Mild increase (5 
to <7 kPa)
Moderate or severe 
increase (≥7 kPa) P- value
n (%) or median [IQR]
All	patients 223 156	(70) 59 (26) 8 (4)
Sex
Male 110 (49) 84	(76) 22 (20) 4 (4) 0.096
Female 113 (51) 72	(64) 37	(33) 4 (4)
Mode of infection
Vertically infected 160	(72) 119	(74) 36 (23) 5 (3) 0.072
Not vertically infected 63 (28) 37	(59) 23	(37) 3 (5)
HCV	genotype
1a/b 121 (55) 86	(71) 31 (26) 4 (3) 0.929
2/3 100 (45) 69 (69) 27	(27) 4 (4)
Centre
Moscow 61	(27) 30 (49) 24 (39) 7	(11) <0.001
St	Petersburg 70	(31) 52	(74) 17	(24) 1 (1)
Krasnoyarsk 92 (41) 74	(80) 18 (20) 0
All	patients
Age	at	the	last	TE,	Median	[IQR] 9.0	[6.3,	13.2] 8.5	[6.0.12.1] 10.7	[6.9,	15.1] 14.6	[11.4,	16.7] 0.003
≤5	y 51 (23) 39	(76) 12 (24) 0
6-	10	y 88 (39) 68	(77) 18 (20) 2 (2)
11-	15	y 53 (24) 33 (62) 17	(32) 3 (6)
>15	y 31 (14) 16 (52) 12 (38) 3 (10)
Vertically	infected	(n	=	160)
Duration of infection/age at the 
last	TE,	Median	[IQR]
7.7	[5.5,	11.0] 7.6	[5.4,	9.9] 8.0	[5.3,	12.9] 13.2	[9.6,	14.1] 0.066
≤5	y 48 (30) 37	(77) 11 (23) 0
6-	10	y 72	(45) 57	(79) 13 (18) 2 (3)
11-	15	y 31 (19) 22	(71) 7	(23) 2 (6)
>15	y 9 (6) 3 (33) 5 (56) 1 (11)
Nonvertically	infected	(n	=	63)
Age	at	the	last	TE,	Median	[IQR] 13.2	[9.4,	17.0] 12.8	[8.8,	16.6] 13.5	[9.5,	17.0] 16.9	[15.1,	17.3] 0.353
≤5	y 3 (5) 2	(67) 1 (33) 0
6-	10	y 16 (25) 11 (69) 5 (31) 0
11-	15	y 22 (35) 11 (50) 10 (45) 1 (5)
>15	y 22 (35) 13 (59) 7	(32) 2 (9)
Duration of diagnosed infection 
at	the	last	TE,	Median	[IQR]
8.5	[2.8,	12.8] 8.5	[3.4,	12.1] 8.6	[1.8,	13.1] 2.7	[0.6,	9.1] 0.429
≤5	y 25 (40) 15 (60) 8 (32) 2 (8)
6-	10	y 19 (30) 10 (53) 8 (42) 1 (5)
>10	y 12 (19) 7	(58) 5 (42) 0
>15	y 7	(11) 5	(71) 2 (29) 0
Treatment	status	at	the	last	TE	(n	=	223)
Not commenced 126	(57) 89	(71) 35 (28) 2 (2) 0.026
Treatment ongoing 15	(7) 6 (0) 8 (53) 1	(7)
Treatment	complete 82	(37) 61	(74) 16 (20) 5 (6)
IQR,	interquartile	range;	TE,	transient	elastography.



























toms	 (Table	3).	 Six	 children	 required	 treatment	 with	 antidepres-
sants	and	one	required	thyroxin	replacement.	Across	all	205	treated	




HCV	 results	 24	weeks	 post-	treatment	 discontinuation	 were	
available	 for	 all	 treated	 patients,	 100	 (49%)	 of	 whom	 had	 SVR24	




and	 30	 (61%)	with	GT2/3)	 (Table	4).	 SVR24	was	more	 common	 in	
those vertically infected (P	=	0.014),	but	the	difference	disappeared	
after adjusting for age at treatment start (P	=	0.216).	Nonvertically	
infected children also had a higher rate of treatment discontinua-
tion	 (Supporting	 information	 Table	 S2).	 Treatment	 outcomes	 var-
ied	 significantly	 by	 centre,	with	 the	 lowest	 proportion	of	 patients	
with	SVR24	in	Moscow	(34%)	and	the	highest	in	Krasnoyarsk	(74%)	
(Supporting	 information	 Table	 S1).	 The	Moscow	 cohort	 had	more	
complex	patients,	more	patients	diagnosed	at	older	ages	and	more	
with	clinical	symptoms	or	elevated	transaminases	at	diagnosis.	More	
patients	 in	Moscow	also	had	 increased	 liver	stiffness	measured	by	
TE	and	bridging	fibrosis	on	liver	biopsy	suggesting	more	progressive	
disease	 (Tables	1	 and	 2;	 Supporting	 information	 Table	 S1).	 Higher	
treatment	discontinuations	 in	 the	Moscow	cohort	 (31%	vs	15%	St	
Petersburg	and	8%	Krasnoyarsk)	(Supporting	information	Table	S1)	
also	partially	explain	the	centre	differences	in	cure	rates.





treatment. Change in z-	scores	did	not	vary	significantly	by	treatment	
type	(P	=	0.326).	The	largest	decreases	in	z-	scores	were	observed	in	
children	aged	10-	15	years	(−0.17	[95%	CI	−0.23,	−0.09])	followed	by	
F IGURE  1 Age at transient 
elastography	(TE)	by	degree	of	liver	




age and liver stiffness (r	=	0.22,	P	=	0.001)











The	most	 frequent	 reason	 for	HCV	 testing	was	HCV	 infection	
in a family member, usually the mother, which coincided with the 
predominance	 of	 vertical	 mode	 of	 transmission	 in	 the	 study	 and	
with national surveillance data.6	Vertical	transmission	of	HCV	so	far	
remains	 the	 only	 nonpreventable	 route	 of	 acquisition	 of	 hepatitis	
C	 infection	 in	 children.	 Notably,	 the	 observed	 proportion	 of	 ver-
tical	 infection	 is	 lower	here	compared	to	 that	 reported	 in	western	
European	children.19
The	 finding	 that	 infection	 possibly	 acquired	 via	 transfusion	
of	blood	components	or	through	invasive	procedures	comprised	
nearly	a	quarter	of	all	cases	here	is	important.	In	the	national	sur-
veillance	 report,	 a	 similar	 proportion	 of	 children	 had	 unknown	
mode of transmission.6	 A	 recent	 outbreak	 of	 hospital-	acquired	
HCV	 infection	 at	 a	 Russian	 children's	 hospital	 in	 the	 Amur	 re-
gion	 highlights	 the	 significance	 of	 the	 problem.20	 Healthcare-	
associated	 HCV	 infections	 are	 almost	 impossible	 to	 confirm	
retrospectively.	History	of	invasive	healthcare	procedures,	when	
vertical	 transmission	 is	 ruled	out,	 can	be	 considered	 as	 a	 proxy	
of	 healthcare-	associated	 infections	 in	 children	 and	 younger	 ad-
olescents, as other routes of transmission such as cosmetic 




gens in health care settings.









than 10 years had bridging fibrosis. Notably, children as young as 
2-	5	years	of	age	had	bridging	fibrosis	highlighting	rapid	progression	
at	 young	 age	 in	 a	minority.	As	 determinants	 of	 liver	 disease	 pro-
gression are uncertain, genetic and other host factors could have 
had	an	 impact	on	 the	particularly	 aggressive	 course	of	disease	 in	
some	children.	Only	 a	 third	of	 children	had	a	 liver	biopsy,	 poten-
tially	reflecting	selection	bias	of	choosing	children	with	suspected	
advanced	 liver	 disease	 for	 the	 invasive	 staging.	 However,	 in	 our	
study	TE	was	 introduced	from	2008	to	2011	 in	different	centres,	
and	prior	to	this	 liver	biopsy	was	the	only	method	of	staging	liver	
disease.	Differences	 in	 local	practices	 and	complexity	of	patients	
likely	played	a	role	as	most	children	with	liver	biopsy	attended	the	
Moscow	 centre.	We	did	 not	 find	 a	 relationship	 between	 age	 and	
advanced	liver	disease;	however,	likelihood	of	liver	biopsy	increased	
with	age	and	it	 is	 likely	that	younger	children	undergoing	biopsies	












a significant correlation between liver 
stiffness	and	biopsy	results	(Tau-	b	=	0.29,	
P	=	0.042)
8  |     TURKOVA eT Al.
Three-	quarters	of	children	had	evaluation	of	liver	stiffness	by	TE,	
used	as	 indirect	assessment	of	 liver	fibrosis.	Greater	 liver	stiffness	
was observed with older age and duration of infection, although only 
two	(1%)	children	had	liver	stiffness	indicative	of	advanced	fibrosis	
(≥9	kPA)	and	six	(3%)	had	a	moderate	increase	(7	to	<9	kPa);	7%	of	







lack	 of	 correlation	 between	 TE	 and	 liver	 biopsy	 for	 nonadvanced	
liver	fibrosis	and	absence	of	validated	data	for	children	with	CHC.22 
High	inter-	and	intra-	observer	variability	of	liver	biopsy	evaluation23 
and	 different	 biopsy	 scoring	 systems	 add	 to	 these	 limitations.	 At	
TABLE  3 Treatment duration, discontinuations, adverse events and outcomes
All
PegIFN alfa- 2b and 
ribavirin
IFN alfa- 2a/b plus 
ribavirin IFN alfa- 2a/b only Other
n (%) or median [IQR]
Total 205 114 13 59 19
Duration of treatment (mo)
All 16	[14,	28] 21	[14,	28] 17	[14,	18] 16	[14,	28] 15	[11,	27]
Genotype	1a/b 28	[16,	28] 28	[28,	28] 16	[14,	23] 17	[15,	28] 27	[8,	28]
Genotype	2/3 14	[14,	15] 14	[14,	14] 15	[14,	17] 15	[14,	26] 15	[14,	16]
Treatment	prematurely	
discontinued
39 (19) 12 (11) 3 (23) 18 (31) 6 (32)
Reasons	for	premature	discontinuationa
Inadequate	response 33 (85) 8	(67) 2	(67) 17	(94) 6 (100)
Drug reactions 6 (15) 5 (42) 0 0 1	(17)
Family	decision 8 (21) 4 (33) 2	(67) 2 (11) 0
Side	effectsa
None 14	(7) 1 (1) 2 (15) 10	(17) 1 (5)
Hypersensitivity	reaction 6 (3) 6 (5) 0 0 0
Diarrhoea 6 (3) 5 (4) 0 1 (2) 0
Nausea/vomiting 20 (10) 17	(15) 1 (8) 2 (3) 0
Hepatotoxicity 4 (2) 2 (2) 0 1 (2) 1 (5)
Hypothyroidism 2 (1) 2 (2) 0 0 0
Hair	loss 39 (19) 34 (30) 1 (8) 4	(7) 0
Poor weight gain/weight 
loss
48 (23) 36 (40) 0 10	(17) 2 (11)
Insomnia 34	(17) 26 (22) 1 (8) 7	(12) 0
Depression/anxiety 32 (16) 19	(17) 1 (8) 10	(17) 2 (11)
Flu-	like	symptoms 186 (91) 110 (96) 11 (85) 48 (81) 17	(89)
Weakness 79	(39) 54	(47) 3 (23) 19 (32) 3 (16)
Local reaction at injection 
site
114 (56) 74	(65) 1 (8) 25 (42) 14	(74)
Anaemia 46 (22) 34 (30) 0 10	(17) 2 (11)
Thrombocytopenia 21 (10) 14 (12) 0 4	(7) 0
Neutropenia 59 (29) 40 (35) 0 15 (25) 4 (21)
Other 21 (10) 19	(17) 0 2 (3) 0
SVR24
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present,	it	is	not	possible	to	confidently	identify	rapid	CHC	progres-






ALL treated PegIFN alfa- 2b + ribavirin only
n (%) No SVR24 SVR24 P- value No SVR24 SVR24 P- value
All 205 105 (51) 100 (49) 49 (43) 65	(57)
Sex
Male 102 (50) 58	(57) 44 (43) 0.108 25 (43) 33	(57) 0.979
Female 103 (50) 47	(46) 56 (54) 24 (43) 32	(57)
Mode of infection
Vertically infected 126 (61) 56 (44) 70	(56) 0.014 36 (44) 45 (56) 0.621
Not vertically infected 79	(39) 49 (62) 30 (38) 13 (39) 20 (61)
HCV	genotypea
1a/b 125 (61) 69 (55) 56 (45) 0.129 29 (45) 35 (55) 0.486
2/3 79	(39) 35 (44) 44 (56) 19 (39) 30 (61)
Multiple	treatments
No 186 (82) 83 (49) 85 (51) 0.268 37	(42) 52 (58) 0.566
Yes 37	(18) 22 (59) 15 (41) 12 (48) 13 (52)
All	patients




10.0	[6.7,	14.1] 8.2	[4.7,	12.0] 0.014 10.0	[7.0,	14.1] 8.6	[6.1,	12.7] 0.435
<2	y 10 (5) 2 (20) 8 (80) 0 0
2-	5	y 45 (22) 20 (44) 25 (56) 9 (36) 16 (64)
6-	10	y 73	(36) 36 (49) 37	(51) 18 (42) 25 (58)
>10	y 77	(38) 47	(61) 30 (39) 22 (48) 24 (52)
Vertically	infected	(n	=	126)
Duration of infection/age 




7.5	[4.9,	11.3] 6.5	[4.2,	9.1] 0.146 8.7	[6.5,	11.6] 7.1	[4.7,	9.8] 0.102
<2	y 10 (8) 2 (20) 8 (80) 0 0
2-	5	y 40 (32) 17	(43) 23 (58) 7	(30) 16	(70)
6-	10	y 48 (38) 22 (46) 26 (54) 16 (46) 19 (54)
>10	y 28 (22) 15 (54) 13 (46) 13	(57) 10 (43)
Nonvertically	infected	(n	=	79)









2-	5	y 5 (6) 3 (60) 2 (40) 2 (100) 0
6-	10	y 25 (32) 14 (56) 11 (44) 2 (25) 6	(75)
>10	y 49 (62) 32 (65) 17	(35) 9 (39) 14 (61)
Duration of diagnosed 




1.4	[0.6,	3.4] 2.3	[1.1,	6.6] 0.047 1.4	[1.0,	4.7] 2.3	[1.2,	8.3] 0.407
<2	y 43 (54) 31	(72) 12 (28) 9 (53) 8	(47)
2-	5	y 16 (20) 8 (50) 8 (50) 1 (25) 3	(75)
6-	10	y 16 (20) 7	(44) 9 (56) 1 (11) 8 (89)
>10	y 4 (5) 3	(75) 1 (25) 2	(67) 1 (33)
IQR,	interquartile	range.
aGenotype	unknown	for	one	patient.	









than	 previously	 thought	may	 develop	 advanced	 liver	 disease	with	
rapid	progression	in	some	children.	These	findings,	together	with	a	
few recent observational studies,25,26 challenge the traditional be-




lighted	poor	mid-	term	prognosis	 in	 individuals	who	 acquired	HCV	
in	 childhood	 with	 33%	 progressing	 to	 cirrhosis	 by	 median	 age	 of	





PegIFN-	based	 treatments	 remain	 the	 only	 currently	 available	











tients, and also their treatment of children from across Russia, with 
joint	follow-	up	with	local	hepatitis	C	clinics	potentially	contributing	





or	neutropenia,	 one	 in	 three	had	hair	 loss	 and	one	 in	 six	 suffered	
from	 anxiety/depression;	 the	 latter	 may	 be	 underestimated	 given	
that young children do not understand or communicate these ad-
verse	events	well.	Consistent	with	previous	studies,32-34 we showed 






and nearly universal occurrence of adverse reactions as indicated 
by	a	93%	rate	in	this	study.	However,	only	IFN-	based	regimes	are	
currently	 approved	 for	 paediatric	 treatment	 in	Russia.	 For	DAAs	
to	be	licensed	in	children,	it	is	required	that	paediatric	studies	are	
conducted	 in	Russia	which	presents	an	additional	hurdle	 to	mak-





most	 countries,	 with	 prohibitive	 costs.	 Middle-	income	 countries	
are	 in	 a	 particularly	 difficult	 situation	 as	 they	 are	 excluded	 from	
voluntary	 licensing	agreements	and	compulsory	 licensing	 is	chal-
lenging	 to	 implement.35,36	 We	 showed	 that	 patients	 completing	
treatment had a significant decrease of liver stiffness measured 
by	 TE,	 suggesting	 that	 treatment	 in	 childhood	maybe	 beneficial.	
In	the	absence	of	DAA-	regimens	for	children,	the	only	treatment	
option	 in	many	countries	are	 IFN-	based	schemes.	So,	 the	ethical	
question	remains	whether	children	with	evidence	of	 liver	disease	
progression	should	wait	for	new	regimens	or	be	treated	now	with	
suboptimal	 but	 available	 treatment.	 The	options	of	 treating	 chil-
dren	with	DAAs	within	prospective	studies	should	be	implemented	
where	possible.
Antenatal	 HCV	 screening	 is	 routine	 in	 Russia6	 and	 presents	 a	
unique	 opportunity	 for	 timely	 intervention	 to	 cure	maternal	HCV	
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